logo
  

CBAK Energy Technology Posts Narrower Loss In Q4

CBAK Energy Technology, Inc. (CBAT) posted a fourth quarter net loss attributable to shareholders of $4.8 million, compared to net loss of $10.7 million in the same period of 2022. Net loss attributable to shareholders after deducting the change in fair value of warrants was $4.8 million, compared to a net loss of $11.7 million, mainly due to the weaker performance of Hitrans, which was affected by the slowdown in the raw materials market. Net income from the battery business was $6.6 million, compared to a net loss of $6.4 million, a year ago.

Net revenues were $56.2 million, an increase of 3.2% compared to $54.5 million in the same period of 2022. The company said the increase was primarily attributable to an increase in revenue from the battery business, partially offset by a decrease in sales from Hitrans, which was affected by the slowdown in the raw materials market. Net revenues from sales of batteries were $36.8 million, an increase of 30.9% from $28.1 million in the same period of 2022.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT